Enveric Reports Distinct Brain-Activity Profile for EB-003 in Preclinical Study

Key Points

• EB-003 altered brain-wave activity in prefrontal and parietal cortical regions in mice, supporting functional activity in the central nervous system.
• Its profile differed from DMT, the classic psychedelic used as a comparator.
• EB-003 did not produce the epileptic-like EEG activity and acute body spasms observed with DMT under the study conditions.
• Enveric plans to evaluate qEEG as a potential biomarker in first-in-human development.
• The findings are preclinical and do not establish safety, effectiveness or an absence of hallucinogenic effects in people.

Enveric Biosciences (NASDAQ: ENVB) reported findings that add to the preclinical evidence for EB-003, its lead candidate for psychiatric and neurological disorders. The company is developing small-molecule neuroplastogenic therapies intended to address unmet mental-health needs.

The mouse study used quantitative electroencephalography, or qEEG, to measure changes in brain electrical activity across multiple frequency bands.

Brain-Wave Findings Differentiate EB-003 From DMT

EB-003 modulated brain-wave oscillations in prefrontal and parietal regions, providing an objective measure of its effects on cortical activity.

Enveric also reported a different neurophysiological signature from DMT. While the comparator produced epileptic-like EEG activity and acute body spasms, EB-003 did not elicit similar findings or disruptive sedation patterns.

These observations support further investigation, but they do not establish that EB-003 is broadly safer than DMT. The supplied information does not provide doses, animal counts, numerical effect sizes or detailed statistical comparisons.

qEEG Could Help Guide Early Human Development

Enveric intends to investigate whether qEEG can connect drug exposure with measurable brain activity in its planned Phase 1 program.

Alongside safety and pharmacokinetic assessments, that information could help identify biologically active doses for subsequent studies. However, a measurable brain-wave change is not itself evidence of symptom improvement, and qEEG’s usefulness for EB-003 in humans remains to be evaluated.

EB-003 is designed to engage 5-HT2A and 5-HT1B receptors with the aim of promoting neuroplasticity without hallucinogenic effects. The current study does not establish that this intended profile will translate to people.

Investor Takeaway: A Potential Development Tool, Not Clinical Validation

For ENVB investors, the principal advance is an objective measure of brain activity that could support early clinical decision-making.

The next substantive test is whether human studies demonstrate acceptable safety, predictable exposure and interpretable pharmacodynamic effects. No Phase 1 start date or human efficacy results were provided.